ENTRY       D09896                      Drug
NAME        Enavatuzumab (USAN/INN)
FORMULA     C6494H10004N1720O2038S48
EXACT_MASS  146227.8643
MOL_WEIGHT  146318.3388
SEQUENCE    (Heavy chain)
            EVQLVESGGG LVQPGGSLRL SCAASGFTFS SYWMSWVRQA PGKGLEWVAE IRLKSDNYAT
            HYAESVKGRF TISRDDSKNS LYLQMNSLRA EDTAVYYCTG YYADAMDYWG QGTLVTVSSA
            STKGPSVFPL APSSKSTSGG TAALGCLVKD YFPEPVTVSW NSGALTSGVH TFPAVLQSSG
            LYSLSSVVTV PSSSLGTQTY ICNVNHKPSN TKVDKKVEPK SCDKTHTCPP CPAPELLGGP
            SVFLFPPKPK DTLMISRTPE VTCVVVDVSH EDPEVKFNWY VDGVEVHNAK TKPREEQYNS
            TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL PAPIEKTISK AKGQPREPQV YTLPPSREEM
            TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL DSDGSFFLYS KLTVDKSRWQ
            QGNVFSCSVM HEALHNHYTQ KSLSLSPGK
            (Light chain)
            DIQMTQSPSS LSASVGDRVT ITCRASQSVS TSSYSYMHWY QQKPGKAPKL LIKYASNLES
            GVPSRFSGSG SGTDFTLTIS SLQPEDFATY YCQHSWEIPY TFGGGTKVEI KRTVAAPSVF
            IFPPSDEQLK SGTASVVCLL NNFYPREAKV QWKVDNALQS GNSQESVTEQ DSKDSTYSLS
            STLTLSKADY EKHKVYACEV THQGLSSPVT KSFNRGEC
            (Disulfide bridge: H22-H98, H146-H202, H263-H323, H369-H427, H228-H'228, H231-H'231, L23-L92, L138-L198, H222-L218)
  TYPE      Peptide
EFFICACY    Antineoplastic
  TYPE      Monoclonal antibody
COMMENT     Treatment of solid tumors
TARGET      TNFRSF12A (TWEAKR, CD266) [HSA:51330] [KO:K05149]
  PATHWAY   hsa04060(51330)  Cytokine-cytokine receptor interaction
BRITE       Target-based classification of drugs [BR:br08310]
             Cytokines and receptors
              Cytokine receptors
               Tumor necrosis factor receptors
                TNFRSF12A (TWEAKR, CD266)
                 D09896  Enavatuzumab (USAN/INN)
DBLINKS     CAS: 1062149-33-0
            PubChem: 124490609
///
